HIV prevention
Gilead Expands HIV Drug Access, Yet Faces Criticism Over Exclusion of Middle-Income Countries
Gilead Sciences, HIV drug access, Lenacapavir, Generic licensing agreements, Middle-income countries exclusion, HIV prevention, Pre-exposure prophylaxis (PrEP)
Gilead Expands Access to Long-Acting HIV PrEP with Licensing Deals for Generic Lenacapavir
Gilead Sciences, lenacapavir, HIV PrEP, generic licensing, long-acting HIV prevention, global health access
Gilead’s Twice-Yearly Lenacapavir Shows 96% HIV Risk Reduction, Paving Way for Regulatory Filings
Gilead Sciences, Lenacapavir, HIV Prevention, Twice-Yearly PrEP, Regulatory Filings, PURPOSE 2 Trial
Gilead’s Twice-Yearly Lenacapavir Shows 96% HIV Risk Reduction, Eyes 2025 Launch for HIV Prevention
Lenacapavir, HIV Prevention, Twice-Yearly Injection, Gilead Sciences, PrEP, PURPOSE 1 and 2 Trials, Regulatory Filings, 2025 Launch
Gilead’s Twice-Yearly PrEP Drug Achieves 100% Efficacy in HIV Prevention
Gilead, PrEP, HIV prevention, lenacapavir, GSK, Apretude, HIV vaccine, HIV treatment